ARTICLE: PDF OnlySafety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian populationSANTOSHAM, MATHURAM MD, MPH; HILL, JANNE BS; WOLFF, MARK PHD; REID, RAYMOND MD; LUKACS, LINDA BS; AHONKHAI, VINCENT MDAuthor Information From the Department of International Health, Division of Disease Control, The Johns Hopkins University School of Hygiene and Public Health, and the Division of Pediatric Infectious Diseases, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD (MS, JH, MW, RR), and Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., West Point, PA (LL, VA). The Pediatric Infectious Disease Journal: February 1991 - Volume 10 - Issue 2 - p 113-116 Free Abstract The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide conjugate vaccine linked to the outer membrane protein complex of Neisseria meningitidis (Hib-OMP) were evaluated among Apache and Navajo infants and children. One dose of the Hib-OMP was given to 42 children who were from 12 and 60 months of age. Ninety-two infants 6 to 8 weeks old were given one dose of Hib-OMP at the time of enrollment. A subsequent dose of the vaccine was given 2 months later and a third dose was offered between 12 and 15 months of age. All the 12− to 60-month-old children achieved a protective antibody concentration (>1 μg/ml) 1 month postvaccination. Among the 6− to 8-week-old infants only 11% of the Apaches and 8% of Navajos had a protective anti-PRP antibody concentration prevaccination. One month post vaccination 68% of the Apaches and 69% of the Navajos had protective anti-PRP antibody concentrations. One month after the second immunization 67% of the Apaches and 75% of Navajos had protective anti-PRP concentrations. Among the infants that received the third (booster) immunization (N = 28) 74% had protective anti-PRP antibody titers just before the booster immunization. One month after the booster immunization all of the infants had protective concentrations of anti-PRP antibody. We conclude that the Hib-OMP is safe and highly immunogenic among Apache and Navajo infants and children. © Williams & Wilkins 1991. All Rights Reserved.